Enliven Therapeutics

Company snapshot

Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into cl

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Enliven Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Enliven Therapeutics.

1. Jun 8, 2026 Clinical update

   ELVN-002-003 — Phase 2

2. Jun 5, 2026 Clinical update

   A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia — Phase 1

3. Jun 5, 2026 Clinical update

   ELVN-001 — Phase 1

4. May 26, 2026 Clinical update

   ELVN-002 — Phase 1

5. May 23, 2026 Clinical update

   ELVN-001 — Phase 1

View all clinical trial activity →

• What is Enliven Therapeutics?

  Enliven Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker ELVN. Primary therapeutic focus areas include Solid Tumors, Colorectal Cancer and Breast Cancer, HER2 Mutant Non-small Cell Lung Cancer, Chronic myeloid leukemia, Chronic M

• Is Enliven Therapeutics publicly traded?

  Yes. Enliven Therapeutics is listed with ticker ELVN on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Enliven Therapeutics develop or market?

  We link 13 drug profile(s) where Enliven Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/enliven-therapeutics#company-drugs.

• What are the latest developments for Enliven Therapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Enliven Therapeutics focus on?

  Enliven Therapeutics focuses on Solid Tumors, Colorectal Cancer and Breast Cancer, HER2 Mutant Non-small Cell Lung Cancer, Chronic myeloid leukemia based on our analysis of their pipeline programs and drug development activities.